Medicine & Life Sciences
Respiratory Syncytial Virus Vaccines
100%
Respiratory Syncytial Viruses
75%
Referral and Consultation
47%
Monoclonal Antibodies
37%
Vaccines
19%
Infant Mortality
14%
Licensure
13%
Neutralizing Antibodies
12%
Half-Life
11%
Cost-Benefit Analysis
11%
Immunization
10%
Income
10%
Virus Diseases
9%
Parturition
8%
Morbidity
7%
Mortality
6%
Child
5%
Population
5%
Agriculture & Biology
Respiratory syncytial virus
96%
vaccine development
79%
monoclonal antibodies
32%
vaccines
31%
infant mortality
12%
efficacy testing
11%
pregnant women
11%
product development
10%
neutralizing antibodies
10%
respiratory tract diseases
9%
cost effectiveness
9%
morbidity
9%
immunization
9%
half life
8%
disease control
8%
income
7%
death
7%
dosage
4%
Social Sciences
WHO
60%
mortality
36%
infant
35%
prophylaxis
28%
pregnant women
23%
morbidity
21%
low income
16%
candidacy
16%
death
15%
income
14%
expert
13%
cause
12%
costs
12%
Group
6%